Mesoblast shares (ASX: MSB) have taken a further drop today, down 4.57% as the pullback from highs that began at the start of the year continues at pace. Whilst the biotech firm has seen its share price plummet 53% since the start of 2025, those with a longer memory may look back to a hugely impressive 2024 for the company, where shares increased some 9x.

This dramatic reversal of fortune follows the euphoric start to the year, fueled by the long-awaited FDA approval of its flagship product, remestemcel-L (marketed as Ryoncil), for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.

The initial surge, which propelled the stock to a four-year high of A$3.37 on January 2nd, has since given way to a stark reality check as investors grapple with the complexities of commercialization, persistent financial losses, and a shifting risk appetite.

The initial optimism surrounding Ryoncil’s approval was understandable. It represented a significant regulatory milestone for Mesoblast, validating years of research and development. However, the subsequent market reaction underscores the crucial difference between regulatory success and commercial viability. The post-approval period has been marked by a gradual erosion of investor confidence, as the market digested the challenges inherent in launching a novel therapy in a competitive pharmaceutical landscape.

One of the key factors contributing to the share price decline has been the dilutive effect of capital raising activities. In January, Mesoblast completed a A$260 million private placement to institutional investors at a discounted price of A$2.50 per share. While this infusion of capital was undoubtedly necessary to fund the commercial rollout of Ryoncil and further research initiatives, it came at the expense of existing shareholders, particularly retail investors excluded from the offering. The resulting dilution triggered an immediate 9% drop in the share price, signaling a shift in sentiment.

 

Top Australian Brokers

 

Here’s a look at some of the headlines on a timeline:

  • December 2024 – FDA approval of Ryoncil (remestemcel-L) for treatment of steroid-refractory acute graft-versus-host disease in children
  • January 2025 – Share price peaks at A$3.37 (four-year high) following FDA approval
  • January 2025 – A$260 million capital raising completed through global private placement at A$2.50 per share (11% discount), resulting in share dilution
  • March 2025 – Significant increase in short positions with approximately 20 million shares shorted over a one-month period
  • April 2025 – 15% decline in share price despite announcing availability of Ryoncil in the United States
  • June 2025 – Current share price at A$1.67, representing a 53% decline from January peak

Furthermore, Mesoblast’s financial performance has continued to weigh heavily on investor confidence. The company has consistently reported net losses, with the most recent half-year loss amounting to A$72.52 million. While this represents an improvement over the previous period’s loss of A$84.20 million, it reinforces the reality that Mesoblast remains some distance from achieving profitability. The market is now demanding tangible evidence of revenue generation from Ryoncil sales to justify the company’s valuation. The estimated earnings for the next half-year are –A$0.06 per share, underscoring the continued challenges.

Beyond company-specific factors, broader market dynamics have also played a role in Mesoblast’s share price decline. Increased short-selling activity, with approximately 20 million shares shorted in a one-month period, suggests a growing bearish sentiment among institutional investors. Moreover, external factors such as global market volatility and geopolitical concerns have added to the overall uncertainty, exacerbating the downward pressure on the stock.

Despite the recent setbacks, analysts remain optimistic about Mesoblast’s long-term prospects. The average one-year price target is A$3.50, implying a significant upside from current levels. However, this bullish outlook depends on the company’s ability to successfully commercialize Ryoncil, secure additional regulatory approvals for its other pipeline products, and ultimately achieve profitability.

Category Bull Case Bear Case
Potential Upside Successful commercialization of Ryoncil leading to significant revenue growth. Positive clinical trial results for other pipeline products driving further regulatory approvals. Strategic partnerships expanding market reach and access to capital. Slow uptake of Ryoncil due to competition and reimbursement challenges. Continued financial losses and need for further dilutive capital raisings. Unfavorable clinical trial outcomes or regulatory setbacks.
Key Catalysts Strong Ryoncil sales figures in upcoming quarters. Positive data readouts from ongoing clinical trials. Announcement of new partnerships or licensing agreements. Disappointing Ryoncil sales performance. Negative clinical trial results or regulatory rejections. Increased competition from alternative therapies.
Risks Commercial execution risk. Regulatory risk. Financial risk. Competition risk. High cash burn rate. Dependence on single product (Ryoncil) for revenue. Negative market sentiment.

The road ahead for Mesoblast has it’s challenges. The company has to deal with the complexities of the US healthcare system, compete with established therapies, and manage its cash burn rate. The key to restoring investor confidence lies in delivering tangible results, demonstrating the clinical and commercial value of its cell-based therapies, and achieving a sustainable path to profitability.

Don’t Buy Just Yet

You will want to see this before you make any decisions.

Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.

Our experts picked out The 5 best ASX shares to buy in 2025.

We’re giving away this valuable research for FREE.

Click below to secure your copy

Secure your FREE copy